Literature DB >> 30694352

Empagliflozin enhances human and murine cardiomyocyte glucose uptake by increased expression of GLUT1.

Julian Mustroph1, Charlotte M Lücht1, Olivia Wagemann1, Thomas Sowa1, Karin P Hammer1, Can M Sag1, Daniel Tarnowski1, Andreas Holzamer2, Steffen Pabel1, Bo Eric Beuthner3, Samuel Sossalla1,3, Lars S Maier1, Stefan Wagner4.   

Abstract

Entities:  

Keywords:  Cardiomyocytes; Empagliflozin; GLUT1; Glucose; Heart failure

Mesh：

Substances：

Year:  2019        PMID： 30694352     DOI： 10.1007/s00125-019-4819-z

Source DB:  PubMed          Journal:  Diabetologia        ISSN： 0012-186X            Impact factor:   10.122


× No keyword cloud information.
  8 in total

Review 1.  Glucose Transporters in Cardiac Metabolism and Hypertrophy.

Authors:  Dan Shao; Rong Tian
Journal:  Compr Physiol       Date:  2015-12-15       Impact factor: 9.090

2.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

Authors:  Bernard Zinman; Christoph Wanner; John M Lachin; David Fitchett; Erich Bluhmki; Stefan Hantel; Michaela Mattheus; Theresa Devins; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Silvio E Inzucchi
Journal:  N Engl J Med       Date:  2015-09-17       Impact factor: 91.245

3.  Cardiac-specific overexpression of GLUT1 prevents the development of heart failure attributable to pressure overload in mice.

Authors:  Ronglih Liao; Mohit Jain; Lei Cui; Jessica D'Agostino; Francesco Aiello; Ivan Luptak; Soeun Ngoy; Richard M Mortensen; Rong Tian
Journal:  Circulation       Date:  2002-10-15       Impact factor: 29.690

4.  MiR-421 inhibits the malignant phenotype in glioma by directly targeting MEF2D.

Authors:  Liang Liu; Sitong Cui; Rui Zhang; Yan Shi; Liangsheng Luo
Journal:  Am J Cancer Res       Date:  2017-04-01       Impact factor: 6.166

5.  Downregulation of metabolic gene expression in failing human heart before and after mechanical unloading.

Authors:  Peter Razeghi; Martin E Young; Jun Ying; Christophe Depre; Ivan P Uray; June Kolesar; Gregory L Shipley; Christine S Moravec; Peter J A Davies; O H Frazier; Heinrich Taegtmeyer
Journal:  Cardiology       Date:  2002       Impact factor: 1.869

6.  Role of late sodium current as a potential arrhythmogenic mechanism in the progression of pressure-induced heart disease.

Authors:  Karl Toischer; Nico Hartmann; Stefan Wagner; Thomas H Fischer; Jonas Herting; Bernhard C Danner; Can M Sag; Thomas J Hund; Peter J Mohler; Luiz Belardinelli; Gerd Hasenfuss; Lars S Maier; Samuel Sossalla
Journal:  J Mol Cell Cardiol       Date:  2013-04-06       Impact factor: 5.000

7.  Empagliflozin reduces Ca/calmodulin-dependent kinase II activity in isolated ventricular cardiomyocytes.

Authors:  Julian Mustroph; Olivia Wagemann; Charlotte M Lücht; Maximilian Trum; Karin P Hammer; Can Martin Sag; Simon Lebek; Daniel Tarnowski; Jörg Reinders; Filippo Perbellini; Cesare Terracciano; Christof Schmid; Simon Schopka; Michael Hilker; York Zausig; Steffen Pabel; Samuel T Sossalla; Frank Schweda; Lars S Maier; Stefan Wagner
Journal:  ESC Heart Fail       Date:  2018-08

8.  Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits.

Authors:  Antonius Baartscheer; Cees A Schumacher; Rob C I Wüst; Jan W T Fiolet; Ger J M Stienen; Ruben Coronel; Coert J Zuurbier
Journal:  Diabetologia       Date:  2016-10-17       Impact factor: 10.122
  8 in total
  5 in total

Review 1.  Cardiac metabolic remodelling in chronic kidney disease.

Authors:  Nikayla Patel; Muhammad Magdi Yaqoob; Dunja Aksentijevic
Journal:  Nat Rev Nephrol       Date:  2022-05-30       Impact factor: 42.439

Review 2.  SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects.

Authors:  Anastasios Tentolouris; Panayotis Vlachakis; Evangelia Tzeravini; Ioanna Eleftheriadou; Nikolaos Tentolouris
Journal:  Int J Environ Res Public Health       Date:  2019-08-17       Impact factor: 3.390

Review 3.  Sodium-glucose cotransporter 2 inhibition: towards an indication to treat diabetic kidney disease.

Authors:  Jose Luis Górriz; Juan F Navarro-González; Alberto Ortiz; Ander Vergara; Julio Nuñez; Conxita Jacobs-Cachá; Alberto Martínez-Castelao; Maria Jose Soler
Journal:  Nephrol Dial Transplant       Date:  2020-01-01       Impact factor: 5.992

Review 4.  Direct cardiac effects of SGLT2 inhibitors.

Authors:  Sha Chen; Ruben Coronel; Markus W Hollmann; Nina C Weber; Coert J Zuurbier
Journal:  Cardiovasc Diabetol       Date:  2022-03-18       Impact factor: 9.951

5.  Decreased GLUT1/NHE1 RNA expression in whole blood predicts disease severity in patients with COVID-19.

Authors:  Julian Mustroph; Julian Hupf; Frank Hanses; Katja Evert; Maria J Baier; Matthias Evert; Christine Meindl; Stefan Wagner; Ute Hubauer; Gabriela Pietrzyk; Simon Leininger; Stephan Staudner; Manuel Vogel; Stefan Wallner; Markus Zimmermann; Samuel Sossalla; Lars S Maier; Carsten Jungbauer
Journal:  ESC Heart Fail       Date:  2020-11-20
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.